Relaxin, a pleiotropic vasodilator for the treatment of heart failure

被引：0
作者：
Sam L. Teichman
Elaine Unemori
Thomas Dschietzig
Kirk Conrad
Adriaan A. Voors
John R. Teerlink
G. Michael Felker
Marco Metra
Gad Cotter
机构：
[1] Corthera Inc.,Department of Cardiology and Angiology
[2] Charité Hospital – University Medicine,Department of Physiology and Functional Genomics
[3] University of Florida College of Medicine,Department of Cardiology, Thoraxcenter
[4] University Medical Center Groningen,Section of Cardiology, Veterans Affairs Medical Center
[5] University of California,Department of Cardiology
[6] Duke Clinical Research Institute,Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine
[7] University of Brescia,undefined
[8] Momentum Research Inc.,undefined
来源：
Heart Failure Reviews | 2009年 / 14卷
关键词：
Relaxin; Acute heart failure; Vasodilator; Hemodynamic; Renovascular;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Relaxin is a naturally occurring peptide hormone that plays a central role in the hemodynamic and renovascular adaptive changes that occur during pregnancy. Triggering similar changes could potentially be beneficial in the treatment of patients with heart failure. The effects of relaxin include the production of nitric oxide, inhibition of endothelin, inhibition of angiotensin II, production of VEGF, and production of matrix metalloproteinases. These effects lead to systemic and renal vasodilation, increased arterial compliance, and other vascular changes. The recognition of this has led to the study of relaxin for the treatment of heart failure. An initial pilot study has shown favorable hemodynamic effects in patients with heart failure, including reduction in ventricular filling pressures and increased cardiac output. The ongoing RELAX-AHF clinical program is designed to evaluate the effects of relaxin on the symptoms and outcomes in a large group of patients admitted to hospital for acute heart failure. This review will summarize both the biology of relaxin and the data supporting its potential efficacy in human heart failure.
引用
收藏
页码：321 / 329
页数：8
相关论文
共 118 条
  • [1] Adams KF(2005)Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100, 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) Am Heart J 149 209-216
  • [2] Fonarow GC(1998)Relaxin activates the L-arginine-nitric oxide pathway in vascular smooth muscle cells in culture Hypertension 31 1240-1247
  • [3] Bani D(1995)Relaxin-induced increased coronary flow through stimulation of nitric oxide production Br J Pharmacol 116 1589-1594
  • [4] Failli P(1999)Relaxin may be the “elusive” renal vasodilatory agent of normal pregnancy Am J Kidney Dis 34 1142-1144
  • [5] Bani-Sacchi T(2004)Relationship between heart failure treatment and development of worsening renal function among hospitalized patients Am Heart J 147 331-338
  • [6] Bigazzi M(2004)Emerging role of relaxin in renal and cardiovascular function Am J Physiol Regul Integr Comp Physiol 287 R250-R261
  • [7] Baylis C(1999)Endothelin mediates renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats Am J Physiol 276 F767-F776
  • [8] Butler J(2004)Relaxin modifies systemic arterial resistance and compliance in conscious, nonpregnant rats Endocrinology 145 3289-3296
  • [9] Forman DE(2002)Acute heart failure: a novel approach to its pathogenesis and treatment Eur J Heart Fail 4 227-234
  • [10] Conrad KP(2008)The pathophysiology of acute heart failure—Is it all about fluid accumulation? Am Heart J 155 9-18
12345678910